作者：钱焱，蔡世荣

单位：中山大学附属第一医院胃肠外科中心，广东 广州 510080

Authors: Qian Yan, Cai Shirong

Unit：Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong, China

摘要：

胃癌是全球癌症发病率第五、死亡率第四的恶性肿瘤；而我国的胃癌发病率居世界第一。胃癌具有发病隐匿、异质性强、预后差等特点，很多患者在初诊时已是晚期，药物治疗是其主要治疗手段，也是胃癌研究的热点。近年来随着免疫治疗、靶向治疗的进步，胃癌的药物治疗也取得了不少突破，但也面临着新的挑战。本文就2023—2024 年胃癌在免疫治疗和靶向治疗领域取得的进展和突破进行述评，也提出了在当前这个免疫后时代胃癌靶免治疗所面临的难点和挑战，以期为未来胃癌药物治疗的进一步探索提供思路和建议。

关键词： 胃癌；免疫治疗；靶向治疗

Abstract：

Gastric cancer (GC) is the fifth morbidity and the fourth mortality of cancer in the world. The incidence of GC in China ranks first in the world. GC has the characteristics of occult onset, strong heterogeneity and poor prognosis. Majority patients are first diagnosed in the advanced stage. Drugs are the main treatment method for GC and a hot spot of GC research. In recent years, with the rapid progress of immunotherapy and targeted therapy, the drug therapy has made many breakthroughs. However, we are facing multiple challenges about it. We reviewed the progress and breakthrough made in the field of immunotherapy and targeted therapy for GC in 2023-2024, and put forward the difficulties and challenges currently in order to provide ideas and suggestions for further exploration of drug therapy for GC in future.

Key Words:  Gastric cancer;  Immunotherapy;  Targeted therapy

注：网络优先发布